Results 71 to 80 of about 1,605,786 (390)

Biopsies in oncology

Diagnostic and Interventional Imaging, 2014
Imaging-guided percutaneous biopsies in patients in oncology provide an accurate diagnosis of malignant tumors. Percutaneous biopsy results are improved by correct use of sampling procedures. The risks of percutaneous biopsy are low and its complications are generally moderate.
C. de Bazelaire, A. Coffin, E. de Kerviler, A Scemama, S. Cohen   +4 more
openaire   +2 more sources

Cell‐free and extracellular vesicle microRNAs with clinical utility for solid tumors

Molecular Oncology, EarlyView.
Cell‐free microRNAs (cfmiRs) are small‐RNA circulating molecules detectable in almost all body biofluids. Innovative technologies have improved the application of cfmiRs to oncology, with a focus on clinical needs for different solid tumors, but with emphasis on diagnosis, prognosis, cancer recurrence, as well as treatment monitoring.
Yoshinori Hayashi, Janelle‐Cheri Millen, Romela Irene Ramos, Jennifer A. Linehan, Timothy G. Wilson, Dave S. B. Hoon, Matias A. Bustos   +6 more
wiley   +1 more source

Transcriptional profiles of circulating tumor cells reflect heterogeneity and treatment resistance in advanced prostate cancer

Journal of Experimental & Clinical Cancer Research
Purpose New biomarkers for the detection and monitoring of aggressive variant prostate cancer (AVPC) including therapy-induced neuroendocrine prostate cancer (NEPC) are urgently needed, as measuring prostate-specific antigen (PSA) is not reliable in ...
Lina Bergmann, Sarah Greimeier, Sabine Riethdorf, Tina Rohlfing, Moritz Kaune, Tobias Busenbender, Nadja Strewinsky, Sergey Dyshlovoy, Simon Joosse, Sven Peine, Klaus Pantel, Gunhild von Amsberg, Stefan Werner   +12 more
doaj   +1 more source

Exosomal miRNA profile as complementary tool in the diagnostic and prediction of treatment response in localized breast cancer under neoadjuvant chemotherapy

Breast Cancer Research, 2019
Background Breast cancer patients under neoadjuvant chemotherapy includes a heterogeneous group of patients who eventually develop distal disease, not detectable by current methods.
Alba Rodríguez-Martínez, Diego de Miguel-Pérez, Francisco Gabriel Ortega, José Luis García-Puche, Inmaculada Robles-Fernández, José Exposito, Jordi Martorell-Marugan, Pedro Carmona-Sáez, María del Carmen Garrido-Navas, Christian Rolfo, Hugh Ilyine, José Antonio Lorente, Marta Legueren, María José Serrano   +13 more
doaj   +1 more source

A biopsy is more than a biopsy [PDF]

Journal of General Internal Medicine, 1998
This issue of JGIM contains a review, by Alguire, about commonly performed skin-biopsy procedures that serves as a comprehensive reference for generalists.1 Generalists need to know more than biopsy technique, however, especially now that managed care is pressuring them to do more themselves and to refer less to consultants like dermatologists.
openaire   +2 more sources

A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy.

JAMA Oncology, 2016
IMPORTANCE Overdiagnosis and overtreatment of indolent prostate cancer (PCA) is a serious health issue in most developed countries. There is an unmet clinical need for noninvasive, easy to administer, diagnostic assays to help assess whether a prostate ...
J. McKiernan, M. Donovan, V. O'Neill, S. Bentink, M. Noerholm, S. Belzer, J. Skog, M. Kattan, A. Partin, G. Andriole, G. Brown, John T. Wei, I. Thompson, P. Carroll   +13 more
semanticscholar   +1 more source

KRAS and GNAS mutations in cell‐free DNA and in circulating epithelial cells in patients with intraductal papillary mucinous neoplasms—an observational pilot study

Molecular Oncology, EarlyView.
This study demonstrates that KRAS and GNAS mutations are more prevalent in patients with resected intraductal papillary mucinous neoplasms (IPMN) compared to those under clinical surveillance. GNAS mutations significantly differ between the two patient cohorts, indicating that their absence may serve as a potential biomarker to support conservative ...
Christine Nitschke, Marie Tölle, Philipp Walter, Kira Meißner, Mara Goetz, Jolanthe Kropidlowski, Andreas W. Berger, Jakob R. Izbicki, Felix Nickel, Thilo Hackert, Klaus Pantel, Harriet Wikman, Faik G. Uzunoglu   +12 more
wiley   +1 more source

Clinical heterogeneity in a family with flail arm syndrome and review of hnRNPA1‐related spectrum

Annals of Clinical and Translational Neurology, Volume 9, Issue 12, Page 1910-1917, December 2022., 2022
Abstract Objective Flail arm syndrome (FAS) is one of the atypical subtypes of amyotrophic lateral sclerosis (ALS). Mutations in hnRNPA1 encoding heterogeneous nuclear ribonucleoprotein (hnRNP) A1 are a rare genetic cause of ALS. Herein, marked clinical heterogeneity of FAS in a pedigree with a known hnRNPA1 variant was described to raise early ...
Xiaochen Han, Feixia Zhan, Yuxin Yao, Li Cao, Jianguo Liu, Sheng Yao   +5 more
wiley   +1 more source

Variation in correlation between prognosis and histologic feature based on biopsy selection [PDF]

arXiv, 2020
Glioblastoma multiform carries a dismal prognosis with poor response to gold standard treatment. Innovative data analysis methods have been developed to characterize tumor genomic expression with histologic features. In a clinical setting, biopsy selection methods may be constrained by time and financial burden to the patient.
arxiv  

Final trial report of sentinel-node biopsy versus nodal observation in melanoma.

New England Journal of Medicine, 2014
BACKGROUND Sentinel-node biopsy, a minimally invasive procedure for regional melanoma staging, was evaluated in a phase 3 trial. METHODS We evaluated outcomes in 2001 patients with primary cutaneous melanomas randomly assigned to undergo wide excision ...
D. Morton, J. Thompson, A. Cochran, N. Mozzillo, O. Nieweg, D. Roses, H. J. Hoekstra, C. Karakousis, C. Puleo, B. Coventry, M. Kashani-Sabet, B. M. Smithers, Eberhard Paul, W. Kraybill, J. Mckinnon, He-jing Wang, R. Elashoff, M. Faries   +17 more
semanticscholar   +1 more source